These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 20304456)

  • 1. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms.
    Shedlock DJ; Bailey MA; Popernack PM; Cunningham JM; Burton DR; Sullivan NJ
    Virology; 2010 Jun; 401(2):228-35. PubMed ID: 20304456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.
    Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
    Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The induction and characterization of monoclonal antibodies specific to GP of Ebola virus.
    Tian X; Chen D; Wang H; Xu S; Zhu L; Wu X; Wu Z
    J Med Virol; 2020 Aug; 92(8):996-1006. PubMed ID: 31663613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies.
    Ilinykh PA; Huang K; Santos RI; Gilchuk P; Gunn BM; Karim MM; Liang J; Fouch ME; Davidson E; Parekh DV; Kimble JB; Pietzsch CA; Meyer M; Kuzmina NA; Zeitlin L; Saphire EO; Alter G; Crowe JE; Bukreyev A
    Cell Host Microbe; 2020 Jun; 27(6):976-991.e11. PubMed ID: 32320678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization.
    Gilchuk P; Murin CD; Milligan JC; Cross RW; Mire CE; Ilinykh PA; Huang K; Kuzmina N; Altman PX; Hui S; Gunn BM; Bryan AL; Davidson E; Doranz BJ; Turner HL; Alkutkar T; Flinko R; Orlandi C; Carnahan R; Nargi R; Bombardi RG; Vodzak ME; Li S; Okoli A; Ibeawuchi M; Ohiaeri B; Lewis GK; Alter G; Bukreyev A; Saphire EO; Geisbert TW; Ward AB; Crowe JE
    Immunity; 2020 Feb; 52(2):388-403.e12. PubMed ID: 32023489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and molecular basis for Ebola virus neutralization by protective human antibodies.
    Misasi J; Gilman MS; Kanekiyo M; Gui M; Cagigi A; Mulangu S; Corti D; Ledgerwood JE; Lanzavecchia A; Cunningham J; Muyembe-Tamfun JJ; Baxa U; Graham BS; Xiang Y; Sullivan NJ; McLellan JS
    Science; 2016 Mar; 351(6279):1343-6. PubMed ID: 26917592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
    Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
    Front Immunol; 2021; 12():706757. PubMed ID: 34335620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for differential neutralization of ebolaviruses.
    Bale S; Dias JM; Fusco ML; Hashiguchi T; Wong AC; Liu T; Keuhne AI; Li S; Woods VL; Chandran K; Dye JM; Saphire EO
    Viruses; 2012 Apr; 4(4):447-70. PubMed ID: 22590681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk.
    King LB; West BR; Moyer CL; Gilchuk P; Flyak A; Ilinykh PA; Bombardi R; Hui S; Huang K; Bukreyev A; Crowe JE; Saphire EO
    Nat Commun; 2019 Apr; 10(1):1788. PubMed ID: 30996276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
    Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
    J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope.
    West BR; Moyer CL; King LB; Fusco ML; Milligan JC; Hui S; Saphire EO
    mBio; 2018 Sep; 9(5):. PubMed ID: 30206174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein.
    Koellhoffer JF; Chen G; Sandesara RG; Bale S; Saphire EO; Chandran K; Sidhu SS; Lai JR
    Chembiochem; 2012 Nov; 13(17):2549-57. PubMed ID: 23111988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.
    Reynard O; Volchkov VE
    J Infect Dis; 2015 Oct; 212 Suppl 2():S372-8. PubMed ID: 26232760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential requirements for FcγR engagement by protective antibodies against Ebola virus.
    Bournazos S; DiLillo DJ; Goff AJ; Glass PJ; Ravetch JV
    Proc Natl Acad Sci U S A; 2019 Oct; 116(40):20054-20062. PubMed ID: 31484758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inter-residue network model to identify mutational-constrained regions on the Ebola coat glycoprotein.
    Quinlan DS; Raman R; Tharakaraman K; Subramanian V; Del Hierro G; Sasisekharan R
    Sci Rep; 2017 Apr; 7():45886. PubMed ID: 28397835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design.
    Khurana S; Ravichandran S; Hahn M; Coyle EM; Stonier SW; Zak SE; Kindrachuk J; Davey RT; Dye JM; Chertow DS
    Cell Host Microbe; 2020 Feb; 27(2):262-276.e4. PubMed ID: 32053790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors.
    Meyer M; Yoshida A; Ramanathan P; Saphire EO; Collins PL; Crowe JE; Samal S; Bukreyev A
    Cell Rep; 2018 Aug; 24(7):1816-1829. PubMed ID: 30110638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving cross-reactivity with pan-ebolavirus antibodies.
    King LB; Milligan JC; West BR; Schendel SL; Ollmann Saphire E
    Curr Opin Virol; 2019 Feb; 34():140-148. PubMed ID: 30884329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
    Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE
    Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.